CTN Bulletin logo
June 5, 2018

NIDA Drug Abuse Topics of Interest (DATs) Page



NIDA unveiled a new webpage in May 2018 to be used for posting Drug Abuse Topics of Interest (DATs).

The primary goals of the DATs site are to communicate emerging and continuing areas of research interest for NIDA within the funding section of the NIDA website, leverage the utility of parent funding opportunity announcements, and, ultimately, replace NIDA-specific Program Announcements.

To this end, the new webpage will:

  • Allow NIDA to be more nimble and up to date than PAs (which are issued for 3 years) traditionally allowed.

  • Provide a brief summary of background and objectives for each topic area and immediately connect the research community with contact information for relevant Program Officers.

  • Encourage applicants to use existing parent funding opportunity announcements and include a “code” in the application title and abstract to allow us to track applications submitted in response to DATs.

Note that DATs are not expected to take the place of RFAs, or PARs, or PAs with multiple institutes, and that NIDA continues to encourage investigator-initiated projects in topic areas not listed on the DAT page.

Thanks to all the NIDA staff who contributed to the development and launch of this page, especially Katia Howlett, Michele Rankin, Janet Linton, and Yvonne Walker, who is its steward!

Find the new DATs webpage on the NIDA site at:


CTN Trial Progress

GraphStudy results for Open Studies as of the June 4 trial Progress Report.

CTN-0064 - Linkage to HCV Care.
Enrolled 113

CTN-0067 - CHOICES Scale-Up. Enrolled 17

CTN-0068 - ADAPT-2 for Methamphetamine Use Disorder. Enrolled 197

CTN-0069 - OUD in the Emergency Department. Enrolled 317

CTN-0073 - Detecting Cocaine Use Using Smart watches. Enrolled 19

CTN-0075 - Physician-Pharmacist Collaboration - OUD
Enrolled 33

Total Enrolled in all Studies: 24,802

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Dissemination and Implementation (D&I) Science-Related Events

Webcast: D&I Science: What is it and Why is it Critical to Translational Science?

Registration is open for a free 1-hour webcast on June 19 (12-1pm EDT) on dissemination and implementation science.

Sponsored by the N2 PBRN Virtual Training Series, the Rockefeller University Center for Clinical and Translational Science, and the Clinical Director Network, Inc. (CDN), this webcast will address:

  • What dissemination, implementation, implementation science, and dissemination science are,
  • The features of dissemination and implementation (D&I) research studies and what make them different from usual clinical trials, and
  • How to identify funding sources for D&I researchers.

Speakers: Enola Proctor, PhD, MSW (Washington University), Stephen Bartels, MD, MS (Dartmouth Institute), Laura-Mae Baldwin, MD, MPH (University of Washington). This webcast is pending for up to 1.0 Continuing Medical Education credits from the AAFRP. All continuing education credits will be provided free of charge. Register today!

11th Annual Conference on the Science of D&I in Health

By outlining the priorities in the field, the Science of D&I Conference aims to ensure that evidence is used to inform decisions that will improve the health of individuals and communities. Abstract submissions for this year’s conference, to be held December 3-5, 2018 in Washington DC, are now being accepted! The deadline for submissions is Tuesday, July 24th.

Abstracts are encouraged for 3 types of scientific sessions:

  • individual oral presentations,
  • panel presentations, and
  • poster presentations.

A select number of accepted posters may also be invited to participate in a “poster slam” session as well.

Priority will be given to abstracts that address the overcall conference theme, fit well into the conference tracks (read more about this year’s tracks), and present high-quality data to support abstract conclusions. Find out more about the conference and submission process here!

2018 Training Institute for D&I Research

The Office of Behavioral and Social Sciences Research (OBSSR) in coordination with a number of National Institutes of Health (NIH) Institutes and Centers and the U.S. Department of Veterans Affairs (VA), are hosting this training institute to provide participants with a thorough grounding in conducting D&I research in health across all areas of health and health care.

Applications must be received by June 12, 2018! For more information, including eligibility criteria and application instructions, visit the TIDIRH 2018 website.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

News from the Nodes

Florida Node Alliance/CTN-0064 Update

Northeast NodeThe CTN-0064 (Linkage to Hepatitis C Virus (HCV) Care among HIV/HCV Co-infected Substance Users) main trial database was officially locked on May 9, 2018. Congratulations to all participating nodes and sites on reaching this study milestone!

A total of 422 participants were enrolled (Component 1) and 113 were randomized (Component 2). Sites achieved an outstanding retention rate of 95% at both the 6-month and 12-month follow-up time points.

Thank you to all site and node staff for your tireless dedication and commitment to CTN-0064 and the participants we strive to impact:

  • Florida Node Alliance: Jackson Memorial Hospital, Emory University, Temple University, Harbor-UCLA, University of Pittsburgh Medical Center
  • Greater New York Node: St. Luke’s
  • New England Consortium Node: Boston Medical Center and Boston University
  • Mid-Atlantic Node: Johns Hopkins University
  • Ohio Valley Node: John H. Stroger, Jr. Hospital/CORE Center
  • Texas Node: Parkland Health and Hospital System
  • Southern Consortium Node: University of Alabama at Birmingham

Additionally, sites are fast approaching the ancillary study, CTN-0064-A-1 (Determination of Cause of Death Among HIV Infected Sub

Northeast Node

Northeast NodeOn May 24, the Northeast Node welcomed Kinna Thakarar, DO, MPH, to present on "Opioid Use Disorder and Commonly Co-Occurring Conditions: An Infectious Disease Perspective" as part of the Node’s Science Series.

Dr. Thakarar is an infectious disease (ID) and addiction medicine physician with a special interest in health services research related to ID/addiction issues, as well as an Assistant Professor of Medicine at Maine Medical Center -- a partner of the Northeast Node.

In her presentation, Dr. Thakarar reviewed the epidemiology of injection drug use (IDU) and ID. These data demonstrate that people who have an opioid use disorder and  inject drugs often have co-occurring infectious disease conditions such as HIV, hepatitis, and infective endocarditis. For example, physicians report a 25-50% increase in inpatient consultations for infections among people who inject drugs (PWID). The greatest increase in these infections is among young white people, paralleling the increase in opioid-related overdose fatalities in the US. IDU has also been found to be a main risk factor for acute Hepatitis C (HCV) which is a common co-infection with HIV and is becoming more rampant among younger age groups.

Given the recent inundation of patients admitted to hospitals for medical complications related to substance use, hospitals are being presented with a unique opportunity to intervene. Dr. Thakarar and her team at Maine Medical Center (MMC) have developed a clinical checklist for key health issues among PWID, focusing on harm reduction and infection prevention, such as talking with patients about safe injection techniques, PreP (Pre-Exposure Prophylaxis) for HIV prevention, screening for STIs and receiving relevant vaccines/boosters.

In a recent study conducted by Dr. Thakarar and colleagues at MMC, patients with IDU-associated infective endocarditis valve replacement surgery were discharged from MMC without medication-assisted treatment (MAT), and 38% were discharged with an opioid prescription. In response, MMC integrated a MAT program and addiction consult service, along with case management, of these surgical patients to provide needed assistance to improve recovery from valve replacement surgery.

You can view Dr. Thakarar’s presentation on the Northeast Node’s website.

The next session of the Northeast Node’s Science Series will take place on September 28, 2018 from 12-1pm EST: What’s the Point? Harm Reduction through Syringe Exchange in White River Junction and Springfield, VT by Laura Byrne.

Follow the Northeast Node on Twitter and Facebook.

New England Consortium Node

NEC NodeThe McLean Hospital / Harvard Medical School Addictions in 2018 conference was held in Cambridge, Massachusetts on May 18th and 19th. This well-attended (420 participants) annual conference was developed for participants to: 1) summarize the high rates of opioid addiction in the United States; 2) implement appropriate treatment for opioid use disorder; 3) describe the relationship between stress and addiction; 4) learn about prescribing practices for medications to treat substance use disorders; 5) recognize and diagnose cocaine, methamphetamine, and club drug use disorders, and recommend appropriate treatment; 6) understand issues related to medical marijuana and marijuana use disorders; 7) develop strategies for working with patients on the issue of whether to cut down or abstain from substance use; 8) and recognize and treat co-occurring substance use, anxiety, and benzodiazepine use.

Dr. Roger Weiss and Dr. Shelly Greenfield were organizers of the course and many McLean Hospital/Harvard Medical School Faculty and CTN-affiliated investigators, current and past, delivered seminars at the conference, including Hilary S. Connery, MD, Ph.D. and R. Kathryn McHugh, PhD.

The Addictions in 2019 Conference is scheduled for May 3-4, 2019 at the Boston/Cambridge Marriott Hotel in Cambridge, Massachusetts.

Ohio Valley Node

OV NodeMaryhaven site’s opioid treatment lauded by Senator Portman

A recent op-ed in the Washington Post by Ohio Senator Rob Portman gives praise to the treatment program at Maryhaven Inc., a community treatment program within the Ohio Valley Node and long-standing CTN participating study site.

In the article, Senator Portman discusses the role of the private sector in addressing the current opioid epidemic. He offers Maryhaven’s new Addiction Stabilization Center as an example of how private sector funding can combine with government funding to provide effective treatment strategies for opioid use disorder. Read the article here.

Prestera Center collaborating to develop new Quick Response Team for opioid overdose

Prestera Center (OVN; Huntington WV) has been working collaboratively with other community resources to develop Quick Response Teams in order to reach and respond more effectively to opioid overdose survivors.

The city of Huntington, WV has adopted the Colerain Township (OH) model, which was presented at the Annual CTN Scientific Meeting in March, with very impressive results so far. Since the teams have been responding in the community in early December 2017, 40% of the people they have had contact with have decided to enter a treatment or recovery program with one person being admitted within an hour of first contact. Comprehensive efforts to address the opioid epidemic in Huntington, including the Quick Response Teams, have resulted in a significant decrease in reported overdoses as well. Prestera Center is now working to develop a similar Quick Response Team in Charleston, WV. Once again, they are joining partners in that community to develop outreach to overdose survivors based on the Colerain Township model.

Pacific Northwest Node

On May 18, the University of Washington’s Alcohol & Drug Abuse Institute hosted its 3rd Symposium on Marijuana Research in Washington, this year in collaboration with colleagues from Washington State University.

The keynote speaker, Washington State Attorney General Bob Ferguson (pictured), spoke about issues of federal vs. state marijuana laws, and about Washington’s law protecting local jurisdictions’ right to exclude marijuana retail stores even if the product is legal in the state.

Scientists from the UW and WSU presented panels in three focus areas:

  • Marijuana and Vulnerable Populations

  • Cannabinoids: Therapeutic Potential

  • Marijuana Use & Other Substances: Substitution, Combination, or Both?

The event drew approximately 200 researchers, state and local officials, and community partners.

The 2018 agenda, with video, slides, and speaker information, is available here: http://adai.uw.edu/mjsymposium/.

ADAI received funds from Washington’s Marijuana Dedicated Fund to support marijuana research and information dissemination, described in a report covering activities from July 2015-June 2017.

Western States Node

On March 12-13, the National Academies of Science convened a workshop on Integrating Infectious Disease Considerations with Response to the Opioid Epidemic. Dr. Korthuis served on the planning committee and as a moderator.

The workshop brought together stakeholders and policymakers to develop strategies to integrate treatment for opioid use disorder and HIV, hepatitis C, and hospitalizations for serious infections related to injection drug use.

The CTN-0067 protocol is up and running with all sites endorsed for enrolling participants. As of March 23, 2017, there have been a total of 16 people randomized. We are excited for participants to be induced on XR-NTX and commend all the sites for their efforts to date. As a reminder they protocol is looking for HIV-infected participants with untreated opioid use disorder and HIV RNA pcr with greater-or-equal-to 200 copies/ml.

On March 23, the OHSU-PSU School of Public Health held a retirement reception in honor of Dennis McCarty.

The event reminded us of the decades of contributions Dr. McCarty has given to the field of Addiction. We have all benefited from working with him and he will be missed greatly. (Pictured: Dennis & Sarah McCarty )

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Updates to the National Drug Abuse Treatment Clinical Trials Toolbox

The CTN Investigator Toolbox is an online resource for CTN investigators. It contains detailed information and guidance documents to help investigators navigate the CTN study process from protocol concept and development through protocol implementation and close-out. The Research Development Committee (RDC) document, which describes the CTN concept submission and review process and procedures, was recently updated in May 2018. Check it out here.

For questions or comments, or if you have suggestions for items you’d like to see added to the Toolbox, please contact Dee Blumberg at dblumberg@emmes.com or Julia Collins at jcollins@emmes.com.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

From the ATTC

May ATTC Messenger featured article: Hepatitis Awareness Month: Dr. Lynn Taylor Works to Eliminate Hepatitis C by Maureen Fitzgerald.

From the ATTC/NIATx Blog:

5 Things Dr. Dennis McCarty Wants You to Know About Treatment and Prevention of OUD

10 Things to Know About Hepatitis

New ATTC Products:
2018 Hepatitis Awareness Month Info Sheet and Bulletin Insert

Also of Interest

Register for AHSR 2018!
Join your colleagues in Savannah, Georgia this October for the 2018 Addiction Health Services Research Conference!

This year's conference is hosted by Augusta University Institute of Public and Preventive Health, University of Georgia Owens Institute for Behavioral Research, University of Georgia School of Public & International Affairs, and Georgia State University School of Social Work. Find out more information and register online.




Published by the CTN Dissemination Library of the Pacific Northwest Node
Alcohol & Drug Abuse Institute, University of Washington

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol & Drug Abuse Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

Unsubscribe | Subscribe

Copyright (C) 2016 Alcohol and Drug Abuse Institute. All rights reserved.